Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Akeso Approved for China Trial of Dual PD-1 Bi-Specifics Therapy

publication date: Jan 7, 2022

Akeso, a Hangzhou biopharma, was approved to start a China Phase Ib/II trial of a dual PD-1-based bi-specific therapy for advanced non-small cell lung cancer (NSCLC). The therapy will combine cadonilimab (PD-1/CTLA-4 bi-specific antibody), a first-in-class novel immunotherapy developed by Akeso, with ivonescimab (PD-1/VEGF bi-specific antibody), another Akeso candidate. Akeso said the trial is the world's first study of two combined bi-specific antibodies. Cadonilimab is already under review in China as a second-line therapy for cervical cancer. More details....

Stock Symbol: (HK: 09926)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio Event
Singapore and Digital
April 26-27, 2023
ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China